Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966275 · ClinicalTrials.gov registry record · NA
Post Bariatric Closed Loop Glucagon Trial
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02966275: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02966275 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02966275, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is to test our automated hypoglycemia prevention and treatment device (glucagon-only bionic pancreas) in subjects that have undergone post-bariatric surgery that are experiencing symptoms of hypoglycemia.
Interventions
- DEVICE Glucagon-only bionic pancreas - glucagon
- DEVICE Glucagon-only bionic pancreas - placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02966275
The ClinicalTrials.gov registry entry for NCT02966275 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glucagon-only bionic pancreas - glucagon is the first listed.
NCT02966275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02966275 about?
NCT02966275 is a clinical study titled "Post Bariatric Closed Loop Glucagon Trial". This study is to test our automated hypoglycemia prevention and treatment device (glucagon-only bionic pancreas) in subjects that have undergone post-bariatric surgery that are experiencing symptoms of hypoglycemia.
What is the current status of trial NCT02966275?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2016-09. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02966275?
The interventions under investigation include: Glucagon-only bionic pancreas - glucagon (DEVICE), Glucagon-only bionic pancreas - placebo (DEVICE).
Who is sponsoring clinical trial NCT02966275?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.